Exchange Traded Concepts LLC Decreases Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Exchange Traded Concepts LLC lowered its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 19.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 12,286 shares of the company’s stock after selling 3,031 shares during the period. Exchange Traded Concepts LLC’s holdings in Day One Biopharmaceuticals were worth $171,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. increased its holdings in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after acquiring an additional 1,445 shares during the last quarter. ProShare Advisors LLC increased its holdings in Day One Biopharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock worth $287,000 after acquiring an additional 1,447 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in Day One Biopharmaceuticals by 16.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock worth $376,000 after acquiring an additional 3,900 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Day One Biopharmaceuticals in the 2nd quarter worth about $113,000. Finally, Point72 DIFC Ltd purchased a new stake in Day One Biopharmaceuticals in the 2nd quarter worth about $124,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Down 0.5 %

Shares of DAWN opened at $14.93 on Tuesday. The company has a market cap of $1.30 billion, a PE ratio of -5.95 and a beta of -1.51. The stock has a 50-day moving average price of $14.08 and a 200-day moving average price of $14.37. Day One Biopharmaceuticals, Inc. has a 12-month low of $9.76 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The firm had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. As a group, analysts predict that Day One Biopharmaceuticals, Inc. will post -1.68 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares in the company, valued at $15,606,947.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,748 shares of company stock worth $689,072 in the last quarter. 8.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on DAWN shares. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Finally, Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the company from $11.00 to $24.00 in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.